A- A A+

What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.

Vorspan F, Hjelmström P, Simon N, Benyamina A, Dervaux A, Brousse G, Jamain T, Kosim M, Rolland B.

Expert Opin Drug Deliv. 2019 Sep;16(9):907-914. doi: 10.1080/17425247.2019.1649252.

https://www.tandfonline.com/doi/full/10.1080/17425247.2019.1649252

Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution

Soyka, M. & Pogarell, O. 

Nervenarzt (2019) 90: 932. doi.org/10.1007/s00115-019-0783-6

Abstract

https://link.springer.com/article/10.1007%2Fs00115-019-0783-6

Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines [Internet].

Edge R, Butcher R.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May 9. PMID: 31479216

https://www.ncbi.nlm.nih.gov/books/NBK545816/

Auf der Packungsrückseite: Falsche Wirkstoffgehaltsangabe bei Subutex

Die Firma Indivior ruft eine Charge Subutex 8mg Sublingualtabletten 28 Stück zurück. Der Grund: Auf der Rückseite der Packung ist der falsche Wirkstoffgehalt aufgedruckt. (Deutsche Apotheker Zeitung, 05.09.2019)

https://www.deutsche-apotheker-zeitung.de/news/artikel/2019/09/04-09-2019/falsche-wirkstoffgehaltsangabe-bei-subutex

Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment.

Withey SL, Spealman RD, Bergman J, Paronis CA.

J Pharmacol Exp Ther. 2019 Aug 14. pii: jpet.119.259010. doi: 10.1124/jpet.119.259010

http://jpet.aspetjournals.org/content/early/2019/08/14/jpet.119.259010.long

Norbuprenorphine and respiratory depression: Exploratory analyses with new lyophilized buprenorphine and sublingual buprenorphine
.

Strang J, Knight A, Baillie S, Reed K, Bogdanowicz K, Bell J.

Int J Clin Pharmacol Ther. 2018 Feb;56(2):81-85. doi: 10.5414/CP203118.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29231163

SUBOXONE® (buprenorphine and naloxone) sublingualfilm CIII – RISK EVALUATION AND MITIGATION STRATEGY (REMS)

Buprenorphine (opioid partial agonist‐antagonist) Naloxone (opioidantagonist)

Initial REMS approval: 08/2010, Most recent modification: 04/2014 NDA 22‐410  

Reckitt Benckiser Pharmaceuticals Inc.

https://www.fda.gov/media/79068/download

Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.

Wachman EM, Saia K, Miller M, Valle E, Shrestha H, Carter G, Werler M, Jones H.

Clin Ther. 2019 Jul 27. pii: S0149-2918(19)30346-7. doi: 10.1016/j.clinthera.2019.07.003.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31358302

Buprenorphine in the United States: Motives for abuse, misuse, and diversion.

Chilcoat HD, Amick HR, Sherwood MR, Dunn KE.

J Subst Abuse Treat. 2019 Sep;104:148-157. doi: 10.1016/j.jsat.2019.07.005. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31370979

Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol.

Terasaki D, Smith C, Calcaterra SL.

Pharmacotherapy. 2019 Jul 26. doi: 10.1002/phar.2313.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31348544

Successful Treatment of Opioid Dependence with Flexible Doses of Injectable Prolonged Release Buprenorphine.

Oscar D’Agnone 

Case Reports in Psychiatry, vol. 2019, Article ID 9381346, 4 pages, 2019. doi.org/10.1155/2019/9381346.

https://www.hindawi.com/journals/crips/2019/9381346

Meta-Opinion. What place for prolonged-release buprenorphine depot formulations (Buvidal®) in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.

Vorspan F, Hjelmström P, Simon N, Benyamina A, Dervaux A, Brousse G, Jamain T, Kosim M, Rolland B.

Expert Opin Drug Deliv. 2019 Jul 31. doi: 10.1080/17425247.2019.1649252.

https://www.tandfonline.com/doi/full/10.1080/17425247.2019.1649252

Vielversprechend: Suchtexpert*innen präsentieren erste Praxis-Erfahrungen mit Depot Buvidal®

Mannheim/Lund. Seit Anfang des Jahres in Deutschland verfügbar, liegen nun erste Erfahrungen mit dem neuen Buprenorphin-Depot Buvidal®zur Behandlung der Opioidabhängigkeit bei unterschiedlichen Patiententypen vor. Beim 20. Interdisziplinären Kongress für Suchtmedizin Anfang Juli in München gaben Expert*innen aus der Praxis Einblick in ihre vielfältigen Patienten-Fälle. (Camurus, 07.08.2019)

Buvidal - Symposium - Kongress München 2019

Comparing the Effects of Methadone, Buprenorphine, and Opium Tincture Maintenance Therapy on Sexual Function.

Kheradmand A, Fazeli A, Mazaheri Meybodi A.

Addict Health. 2019 Apr;11(2):120-128. doi: 10.22122/ahj.v11i2.232.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6633070/

Offering Emergency Buprenorphine Without a Prescription.

Roy PJ, Stein MD. 

JAMA.Published online July 08, 2019. doi:10.1001/jama.2019.8309

https://jamanetwork.com/journals/jama/fullarticle/2737850

Buprenorphine for Opioid Use Disorder: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines [Internet].

Marchand DK, Young C, Loshak H.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Apr 24.

https://www.ncbi.nlm.nih.gov/books/NBK543511/

Epidemiology of severe buprenorphine exposures reported to the U.S. Poison Centers.

Rege SV, Ngo DA, Ait-Daoud N, Holstege CP.

Drug Alcohol Depend. 2019 Jul 16;202:115-122. doi: 10.1016/j.drugalcdep.2019.05.015.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31344599

USA. In den USA erzielt ein Vergleich über Opioid-Vermarktung einen neuen Rekord

Der britische Konzern Reckitt Benckiser lässt die Abwehr einer Strafklage 1,4 Milliarden Dollar kosten. Es geht um das Medikament Suboxone, das zur Suchtbehandlung angeboten wurde. Die Anklage fordert in einem weiteren Fall zum gleichen Medikament mindestens drei Milliarden Strafe. (Neue Zürcher Zeitung, 12.07.2019)

https://www.nzz.ch/international/vergleich-ueber-opioid-vermarktung-in-usa-erzielt-neuen-rekord-ld.1495714

USA. Reckitt Benckiser zahlt Milliardenstrafe in den USA

London – Reckitt Benckiser legt den Streit mit den US-Behörden wegen verbotener Marketingmethoden für sein Kombinationspräparat Suboxone Film mit einer Milliardenzahlung bei. (aerzteblatt.de, 11.07.2019)

https://www.aerzteblatt.de/nachrichten/104566/Reckitt-Benckiser-zahlt-Milliardenstrafe-in-den-USA

Free Clinical Update Special Edition - Espranor®

This clinical update focuses on Espranor® (bup-lyo), the lyophilized (rapid-disintegrating) buprenorphine tablet for opioid use disorder (OUD), produced by Ethypharm, which has been available since January 2017. (SMMGP - Supporting good practice in drug and alcohol treatment and and FDAP - Federation of Drug & Alcohol Practitioners, UK, 18.06.2019)

https://www.smmgp-fdap.org.uk/news/free-clinical-update-special-edition-espranor

Erste Behandlungserfahrungen mit wöchentlichem und monatlichem subkutanem Buprenorphin-Depot in Deutschland (Poster)

Claus Schubert, Nikolaus Springer, Antje Breske.

Das erste wöchentliche/monatliche subkutane Buprenorphin-Depot (Buvidal®) wurde im Februar 2019 in Deutschland eingeführt. Hier sollen die ersten praktischen Behandlungserfahrungen aus einer Praxis in Hessen dargestellt werden. (20. Interdisziplinärer Kongress für Sucht-Medizin, 04.07. bis 06.07.2019 in München)

Buvidal. Erste Behandlungserfahrungen ... in Deutschland – Poster.pdf

Erfahrungen nach der Zulassung mit dem wöchentlichen und monatlichen subkutanen Buprenorphin-Depot im Praxisalltag: Fragen an Medical Information und Antworten. (Poster)

Anfragen, die Camurus MIS per E-Mail oder Telefon erhielt, wurden nach Themen kategorisiert und in eine Datenbank aufgenommen, zusammen mit der Antwort an den Fragesteller.

Antje Breske, Peter Hjelmström, Elin Banke Nordbeck, Ayana Gibbs, Lisa Bubb, Karl-Heinz Meller. (20. Interdisziplinärer Kongress für Sucht-Medizin, 04.07. bis 06.07.2019 in München)

Buvidal. Erfahrungen ... im Praxisalltag – Poster.pdf

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men.

Ziaaddini H, Heshmati S, Chegeni M, Mousavi-Ramezanzade M, Mazhari S.

Addict Health. 2018 Oct;10(4):269-275. doi: 10.22122/ahj.v10i4.679.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593171/

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.

Dong R, Wang H, Li D, Lang L, Gray F, Liu Y, Laffont CM, Young M, Jiang J, Liu Z, Learned SM.

Drugs R D. 2019 Jun 13. doi: 10.1007/s40268-019-0277-9. 

https://link.springer.com/article/10.1007%2Fs40268-019-0277-9

Buvidal®Homepage (im Aufbau)

https://www.buvidal.de/

Indivior Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for SUBOXONE®(buprenorphine and naloxone) Sublingual Film

Slough, UK, 18 June 2019–Indivior PLC (LON: INDV) (the ‘Company’), a global specialty pharmaceutical company with a 20-year legacy of leadershipin developing medicines to treatopioid use disorder (OUD),today announced that the European Medicines Agency (EMA) has completed formal validation of Indivior’s Marketing Authorization Application (MAA) for SUBOXONE Film. Validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process.

http://www.indivior.com/wp-content/uploads/2019/06/EMEA-Suboxone-Film-Validation-approval-press-release_Final.pdf

Buvidal®. Free Clinical Update: Special Edition

This Clinical Update focuses on the new prolonged release subcutaneous buprenorphine injection for opioid use disorder .

The purpose of this update is not to summarise the pharmacological properties of Buvidal®, nor to explain in detail how it works. For this the summary of product characteristics can be consulted (see links below). Instead this update evaluates the evidence base for Buvidal®. Three studies are summarised with individual commentary on the results of each study. A wider discussion then follows about the clinical implications of this exciting new technology. (Substance Misuse Management in General Practice (SMMGP), UK, 17.06.2019)

https://www.smmgp-fdap.org.uk/news/free-clinical-update-special-edition

Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.

Frost, M., Bailey, G. L., Lintzeris, N., Strang, J., Dunlop, A., Nunes, E. V., Jansen, J. B., Frey, L. C., Weber, B., Haber, P., Oosman, S., Kim, S., and Tiberg, F. ( 2019) 

Addiction, doi.org/10.1111/add.14636.

https://onlinelibrary.wiley.com/doi/10.1111/add.14636

Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.

Neale, J. , Tompkins, C. N. and Strang, J. (2019), 

Drug Alcohol Rev.. doi:10.1111/dar.12939

https://onlinelibrary.wiley.com/doi/full/10.1111/dar.12939

FREE WEBINAR: Long-acting Buprenorphine prescribing in criminal justice settings: implications for services

Presenters:

Dr Jake Hard, GP, Chair, RCGP Secure Environments Group 

Professor Adrian Dunlop, School of Medicine and Public Health, University of Newcastle, Australia 

Professor Oscar D’Agnone, Consultant Psychiatrist, Addiction Specialist 

This webinar will include: A background to buprenorphine prescribing in criminal justice settings - Clinical experience from Australia regarding long-acting buprenorphine including its introduction in a prison setting - Clinical experience from the UK including opportunities and challenges for services

Tue, Jun 25, 2019 9:30 PM - 10:30 PM CEST

Substance Misuse Management in General Practice (SMMGP). This webinar has been funded by an educational grant from Camurus.

https://register.gotowebinar.com/register/4526159806194230540